Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Run a search on a company

Piramal Pharma Ltd

Pharmaceuticals & Biotechnology | Small Cap

Piramal Pharma Ltd Health Insights
Health Score : 5.83Health Score : 5.83

Piramal Pharma Ltd, operating within the Healthcare Services sector, shows a mixed financial performance. The company demonstrates strong solvency and growth, with notable increases in operating profit, EPS, asset growth, and net income. Profitability is reasonable, driven by solid returns on capital employed, equity, and assets. However, liquidity appears to be a significant area of concern, and efficiency ratios indicate potential challenges in asset utilization. Financial ratios also reflect some weaknesses, particularly in earnings per share and book value. While coverage ratios are average, the company's growth prospects and profitability offer a positive outlook, but these are counterbalanced by liquidity and efficiency issues. Overall, Piramal Pharma presents a blend of strengths and weaknesses that warrants careful monitoring.

Latest Report

View All
Audited Standalone Financial Results for the Quarter and Year Ended March 31, 2026

Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Overview
Ratio
Financial
Piramal Pharma Ltd Health Insights
Health Score : 5.83Health Score : 5.83

Piramal Pharma Ltd, operating within the Healthcare Services sector, shows a mixed financial performance. The company demonstrates strong solvency and growth, with notable increases in operating profit, EPS, asset growth, and net income. Profitability is reasonable, driven by solid returns on capital employed, equity, and assets. However, liquidity appears to be a significant area of concern, and efficiency ratios indicate potential challenges in asset utilization. Financial ratios also reflect some weaknesses, particularly in earnings per share and book value. While coverage ratios are average, the company's growth prospects and profitability offer a positive outlook, but these are counterbalanced by liquidity and efficiency issues. Overall, Piramal Pharma presents a blend of strengths and weaknesses that warrants careful monitoring.

Latest Report

View All
Audited Standalone Financial Results for the Quarter and Year Ended March 31, 2026

Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Neutral

Overall Valuation Score

Highly Undervalued
Undervalued
Neutral
Overvalued
Highly Overvalued
Neutral

P/E RATIO (TTM)

30.15

Highly Undervalued

Industry Median

28.62

Highly Undervalued
Highly Undervalued

Small Cap Median

27.17

Highly Undervalued

P/E RATIO

-64.86

P/B RATIO

2.59

Neutral

Industry Median

3.17

Neutral
Neutral

Small Cap Median

2.62

Neutral

P/S RATIO

2.38

Undervalued

Industry Median

3.42

Undervalued
Neutral

Small Cap Median

2.55

Neutral

Others

Neutral

PEG RATIO

0.00

Neutral
Overvalued

EV/EBITDA RATIO

24.49

Overvalued

The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹158.9 as on Jun 19, 2026.

Markets Depth NSE

Buy Orders

  1. Bid

    Quantity

    Orders

  2. No buy depth

  3. Total

    0

    0

Sell Orders

  1. Ask

    Quantity

    Orders

  2. No sell depth

  3. Total

    0

    0

BidsOffers
50.00%50.00%

Markets Today NSE

  1. High

    0.00

  2. Low

    0.00

  3. Open

    0.00

  4. Close

    0.00

  5. Prev Close

    0.00

  6. Avg Price

    0.00

  7. Volume

    0

  8. Last Traded Quantity

    0

  9. Last Traded Time

    N/A

Price Movement Indicator

0.00

0.00
Today's Low

0.00
Today's High

Quarterly Report28th Apr 26

Audited Standalone Financial Results for the Quarter and Year Ended March 31, 2026

UNDEFINED SENTIMENT

Growth Ratio Summary
Growth Ratio SummaryGrowth Score : 8.00

Growth ratios suggest strong positive momentum, particularly in operating profit, EPS, asset growth, and net income. However, this is counterbalanced by Revenue growth rate. This indicates strong potential for future expansion and profitability. Strategic investments and market positioning may further enhance growth prospects.

PoorRevenue Growth RatePoor
ExcellentOperating Profit Growth RateExcellent
ExcellentEarnings Per Share (EPS) GrowthExcellent
ExcellentAsset Growth RateExcellent
ExcellentNet Income Growth RateExcellent
Growth RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue Growth Rate3.867.9715.3811.99-3.08
Operating Profit Growth Rate-33.47-33.7990.320.72-36.19
Earnings Per Share (EPS) Growth-109.22430.77-455.07
Asset Growth Rate18.0613.475.452.2916.44
Net Income Growth Rate-54.97-149.47-109.68405.56-458.24
01.

Revenue Growth Rate

02.

Operating Profit Growth Rate

03.

Earnings Per Share (EPS) Growth

04.

Asset Growth Rate

05.

Net Income Growth Rate

Financial Ratio Summary
Financial Ratio SummaryFinancial Score : 4.00

Financial ratios reflect mixed performance. While capital expenditures are well-managed, Adjusted EPS, Cash EPS, Book Value Per Share, and DPS indicate areas needing improvement. This suggests potential challenges in earnings quality and shareholder returns. Strategic financial management is essential to optimize these metrics.

PoorAdjusted Earnings Per Share (Adjusted EPS)Poor
WeakCash Earnings Per Share (Cash EPS)Weak
PoorBook Value Per SharePoor
PoorDividend Per Share (DPS)Poor
ExcellentCapital Expenditures (CapEx)Excellent
Financial RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Adjusted Earnings Per Share (Adjusted EPS)3.24-1.560.120.67-2.2
Cash Earnings Per Share (Cash EPS)8.114.125.746.853.81
Book Value Per Share56.4756.7759.861.3761.51
Dividend Per Share (DPS)00.110.140
Capital Expenditures (CapEx)858945710659877
01.

Adjusted Earnings Per Share (Adjusted EPS)

02.

Cash Earnings Per Share (Cash EPS)

03.

Book Value Per Share

04.

Dividend Per Share (DPS)

05.

Capital Expenditures (CapEx)

Profitability Ratio Summary
Profitability Ratio SummaryProfitability Score : 6.20

Profitability ratios indicate a mixed performance. Strong returns on capital employed, equity, and assets are offset by Gross profit margin, Operating margin and Net Margin. Improving these margins would enhance overall profitability. The weighted average calculation underscores the need for a comprehensive approach to profitability management.

PoorGross Profit MarginPoor
ExcellentReturn on Capital Employed (ROCE)Excellent
ExcellentReturn on Equity (ROE)Excellent
GoodReturn on Assets (ROA)Good
PoorOperating MarginPoor
PoorNet MarginPoor
Profitability RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Profit Margin5.55-0.685.586.871.03
Return on Capital Employed (ROCE)72563
Return on Equity (ROE)5.61-2.750.231.12-3.99
Return on Assets (ROA)7.544.47.949.375.13
Operating Margin14.488.8814.6515.7910.4
Net Margin5.73-2.630.220.99-3.68
01.

Gross Profit Margin

02.

Return on Capital Employed (ROCE)

03.

Return on Equity (ROE)

04.

Return on Assets (ROA)

05.

Operating Margin

06.

Net Margin

Efficiency Ratio Summary
Efficiency Ratio SummaryEfficiency Score : 4.67

Efficiency ratios suggest some operational challenges in asset utilization. While days sales in inventory and receivable days are well managed, turnover ratios for fixed assets, inventory, receivables, and capital indicate potential inefficiencies. Optimizing these turnover rates can improve overall performance. The weighted average calculation highlights the need for a balanced approach to asset management.

PoorFixed Asset Turnover RatioPoor
PoorInventory Turnover RatioPoor
PoorReceivables Turnover RatioPoor
ExcellentDays Sales in Inventory RatioExcellent
ExcellentReceivable DaysExcellent
PoorCapital Turnover RatioPoor
Efficiency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Fixed Asset Turnover Ratio0.950.951.021.130.99
Inventory Turnover Ratio4.734.6443.83.27
Receivables Turnover Ratio3.93.954.164.083.93
Days Sales in Inventory Ratio77.1778.6691.2596.05111.62
Receivable Days93.5992.4187.7489.4692.88
Capital Turnover Ratio0.70.690.770.80.7
01.

Fixed Asset Turnover Ratio

02.

Inventory Turnover Ratio

03.

Receivables Turnover Ratio

04.

Days Sales in Inventory Ratio

05.

Receivable Days

06.

Capital Turnover Ratio

Coverage Ratio Summary
Coverage Ratio SummaryCoverage Score : 6.80

Coverage ratios suggest an average capacity to meet interest and dividend obligations. While interest coverage is adequate, equity dividend coverage indicates room for improvement. Strengthening these ratios would enhance financial security and investor confidence. The weighted average calculation reflects a moderate ability to handle financial obligations.

AverageInterest Coverage RatioAverage
GoodEquity Dividend Coverage RatioGood
Coverage RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Interest Coverage Ratio3.450.651.41.980.48
Equity Dividend Coverage Ratio5.561.225
01.

Interest Coverage Ratio

02.

Equity Dividend Coverage Ratio

Solvency Ratio Summary
Solvency Ratio SummarySolvency Score : 10.00

The company's solvency is strong, indicating a solid long-term financial stability. A high Equity Ratio and low Debt ratios reflect a conservative capital structure, reducing financial risk. This provides a stable foundation for future growth and operational flexibility. This suggests that the company is well-positioned to manage its long-term debt obligations.

ExcellentDebt RatioExcellent
ExcellentDebt to Equity RatioExcellent
ExcellentEquity RatioExcellent
ExcellentDebt To Asset RatioExcellent
Solvency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debt Ratio0.290.340.250.290.35
Debt to Equity Ratio0.410.520.330.410.54
Equity Ratio0.710.660.750.710.65
Debt To Asset Ratio0.220.250.170.220.25
01.

Debt Ratio

02.

Debt to Equity Ratio

03.

Equity Ratio

04.

Debt To Asset Ratio

Liquidity Ratio Summary
Liquidity Ratio SummaryLiquidity Score : 2.00

The liquidity position is weak, suggesting potential difficulties in meeting short-term obligations. This could hinder operational flexibility and increase financial risk. While the healthcare industry can have unique working capital dynamics, maintaining adequate liquidity is crucial for managing day-to-day expenses and unexpected needs. The weighted average calculation considers the past five years, highlighting a consistent challenge.

PoorCurrent RatioPoor
PoorQuick RatioPoor
PoorCash RatioPoor
PoorOperating Cash Flow RatioPoor
Liquidity RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Current Ratio1.351.191.231.521.45
Quick Ratio0.910.770.750.940.88
Cash Ratio0.10.080.110.130.23
Operating Cash Flow Ratio0.240.120.220.230.31
01.

Current Ratio

02.

Quick Ratio

03.

Cash Ratio

04.

Operating Cash Flow Ratio

Peer Comparison With 16 Companies

Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.

NO Company Name Health Score P/E Ratio Valuation OPM EPS Latest Profit & Loss
1J B Chemicals & Pharmaceuticals Ltd8.1449.64Overvalued1107.0041.98709.00
2Gland Pharma Ltd7.9135.27Overvalued1630.0078.881027.00
3Neuland Laboratories Ltd7.8461.14Highly Overvalued574.00283.01364.00
4Granules India Ltd7.7332.77Highly Overvalued1185.0016.17595.00
5Ajanta Pharma Ltd7.7236.27Neutral1395.0075.781056.00
6Alembic Pharmaceuticals Ltd7.5422.23Undervalued1118.0032.58671.00
7Syngene International Ltd7.4456.08Overvalued918.007.55317.00
8Emcure Pharmaceuticals Ltd7.4036.42Neutral1865.0038.66941.00
9ERIS Lifesciences Ltd7.1532.39Neutral1120.0017.61648.00
10Ipca Laboratories Ltd6.3335.26Neutral1979.0044.641184.00
11Piramal Pharma Ltd5.83-64.86Neutral922.005.27-326.00
12Jubilant Pharmova Ltd5.7138.62Neutral1260.001.25398.00
13Natco Pharma Ltd5.6911.22Neutral1436.0071.551418.00
14Wockhardt Ltd5.07153.40Neutral652.0019.51199.00
15Pfizer Ltd3.4545.16Neutral-82.00157.92300.00
16Sanofi India Ltd3.4518.59Neutral491.00134.52413.00
Management Assessment Summary
OrangeBalanced Management

Piramal Pharma's management shows a mixed performance. Revenue growth is positive, with a 3-year compounded sales growth of 12% and a TTM growth of 12%. However, profit growth has been inconsistent, with a 3-year compounded profit growth of -38%, despite a high TTM profit growth of 476%. The company's ROCE and ROE are relatively low, indicating capital efficiency issues. Debt management requires attention, as borrowings have increased. While promoter holding is stable, the decrease in FII holding and increase in DII holding may reflect changing investor sentiment. Overall, management has driven sales, but profitability and capital efficiency need improvement.

Category Metric Value Assessment
PROS Sales Growth (3Y CAGR) 12% Consistent revenue expansion
Sales Growth (TTM) 12% Maintained growth momentum
CONS Profit Growth (3Y CAGR) -38% Significant profit decline
ROCE Low Capital efficiency concerns
AverageFinancial Performance & GrowthAverage
WeakCapital Efficiency & ReturnsWeak
AverageFinancial Health & PrudenceAverage
AverageShareholding & Ownership StructureAverage
01.

Financial Performance & Growth

02.

Capital Efficiency & Returns

03.

Financial Health & Prudence

04.

Shareholding & Ownership Structure

Risk Assessment Summary
OrangeBalanced Risk

Piramal Pharma's risk assessment reveals concerns including segment performance volatility and high tax rates. The increasing cash conversion cycle suggests potential inefficiencies in working capital management. Revenue growth has been positive, and promoter holding remains stable. The overall risk is assessed as Orange, suggesting a need for monitoring and strategic adjustments.

AverageSegment performance volatilityAverage
AverageAccounting quality red flagsAverage
AverageForeign exchange or interest rate exposureAverage
AverageRegulatory compliance cost trendsAverage
01.

Segment performance volatility

02.

Accounting quality red flags

03.

Foreign exchange or interest rate exposure

04.

Regulatory compliance cost trends

0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Market Sentiment

Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bearish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bullish

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 10160.13Bearish
  3. SMA 20161.58Bearish
  4. SMA 50163.25Bearish
  5. EMA 10160.09Bearish
  6. EMA 20161.19Bearish
  7. EMA 50163.22Bearish
  8. DEMA 10158.92Bearish
  9. DEMA 20159.43Bearish
  10. DEMA 50160.49Bearish
  11. TEMA 10158.75Bullish
  12. TEMA 20158.89Bullish
  13. TEMA 50160.00Bearish
  14. MACD-1.36Bearish
  15. ADX17.38Weak Trend
Momentum Indicators (7)
  1. IndicatorValueSignal
  2. RSI33.39Neutral
  3. CCI-120.12Oversold
  4. ROC 9-1.31Bearish
  5. ROC 14-2.51Bearish
  6. ROC 25-2.41Bearish
  7. Stoch K8.01Oversold
  8. Stoch D8.15Oversold
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper165.12Neutral
  3. BB Middle161.58Neutral
  4. BB Lower158.05Neutral
  5. ATR1.41Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI15.80Oversold

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Market Sentiment

Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bearish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 10160.98Bearish
  3. SMA 20163.09Bearish
  4. SMA 50165.05Bearish
  5. EMA 10160.77Bearish
  6. EMA 20162.16Bearish
  7. EMA 50164.89Bearish
  8. DEMA 10159.19Bearish
  9. DEMA 20159.99Bearish
  10. DEMA 50161.43Bearish
  11. TEMA 10158.78Bullish
  12. TEMA 20159.45Bearish
  13. TEMA 50159.52Bearish
  14. MACD-1.70Bearish
  15. ADX10.11Weak Trend
Momentum Indicators (7)
  1. IndicatorValueSignal
  2. RSI34.02Neutral
  3. CCI-131.18Oversold
  4. ROC 9-2.79Bearish
  5. ROC 14-1.83Bearish
  6. ROC 25-1.71Bearish
  7. Stoch K9.90Oversold
  8. Stoch D11.62Oversold
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper168.84Neutral
  3. BB Middle163.09Neutral
  4. BB Lower157.35Neutral
  5. ATR1.96Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI59.41Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Market Sentiment

Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bearish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 10162.87Bearish
  3. SMA 20164.07Bearish
  4. SMA 50169.45Bearish
  5. EMA 10161.93Bearish
  6. EMA 20163.89Bearish
  7. EMA 50166.24Bearish
  8. DEMA 10159.88Bearish
  9. DEMA 20160.64Bearish
  10. DEMA 50166.92Bearish
  11. TEMA 10159.42Bearish
  12. TEMA 20159.73Bearish
  13. TEMA 50N/AN/A
  14. MACD-2.45Bearish
  15. ADX10.49Weak Trend
Momentum Indicators (7)
  1. IndicatorValueSignal
  2. RSI35.43Neutral
  3. CCI-152.28Oversold
  4. ROC 9-5.96Bearish
  5. ROC 14-3.10Bearish
  6. ROC 25-4.13Bearish
  7. Stoch K6.86Oversold
  8. Stoch D8.42Oversold
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper170.02Neutral
  3. BB Middle164.07Neutral
  4. BB Lower158.13Neutral
  5. ATR3.42Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI35.47Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Market Sentiment

Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bearish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (22)
  1. IndicatorValueSignal
  2. SMA 10164.46Bearish
  3. SMA 20168.81Bearish
  4. SMA 50164.81Bearish
  5. SMA 100158.75Bullish
  6. SMA 200173.43Bearish
  7. EMA 10164.67Bearish
  8. EMA 20166.62Bearish
  9. EMA 50165.12Bearish
  10. EMA 100165.21Bearish
  11. EMA 200172.31Bearish
  12. DEMA 10161.86Bearish
  13. DEMA 20165.21Bearish
  14. DEMA 50168.15Bearish
  15. DEMA 100160.27Bearish
  16. DEMA 200159.00Bullish
  17. TEMA 10161.20Bearish
  18. TEMA 20161.42Bearish
  19. TEMA 50171.27Bearish
  20. TEMA 100166.30Bearish
  21. TEMA 200151.47Bullish
  22. MACD-1.50Bearish
  23. ADX19.23Weak Trend
Momentum Indicators (6)
  1. IndicatorValueSignal
  2. RSI40.74Neutral
  3. CCI-112.35Oversold
  4. ROC 14-7.29Bearish
  5. ROC 25-9.69Bearish
  6. Stoch K12.16Oversold
  7. Stoch D18.44Oversold
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper179.97Neutral
  3. BB Middle168.81Neutral
  4. BB Lower157.64Neutral
  5. ATR6.09Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI41.14Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (10)
  1. IndicatorValueSignal
  2. SMA 20158.24Bullish
  3. SMA 50177.10Bearish
  4. EMA 20164.81Bearish
  5. EMA 50174.16Bearish
  6. DEMA 20161.31Bullish
  7. DEMA 50162.40Bullish
  8. TEMA 20167.58Bearish
  9. TEMA 50149.88Bullish
  10. MACD-1.49Bullish
  11. ADX25.88Strong Trend
Momentum Indicators (6)
  1. IndicatorValueSignal
  2. RSI46.74Neutral
  3. CCI-45.35Neutral
  4. ROC 147.89Bullish
  5. ROC 25-4.34Bearish
  6. Stoch K55.35Neutral
  7. Stoch D60.84Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper182.84Neutral
  3. BB Middle158.24Neutral
  4. BB Lower133.64Neutral
  5. ATR13.64Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI79.76Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 6159.04Bullish
  3. SMA 12176.34Bearish
  4. SMA 24197.32Bearish
  5. EMA 6165.16Bullish
  6. EMA 12173.70Bearish
  7. EMA 24173.46Bearish
  8. DEMA 6158.32Bullish
  9. DEMA 12162.37Bullish
  10. DEMA 24N/AN/A
  11. TEMA 6162.16Bullish
  12. TEMA 12150.32Bullish
  13. TEMA 24N/AN/A
  14. MACDN/AN/A
  15. ADX15.52Weak Trend
Momentum Indicators (6)
  1. IndicatorValueSignal
  2. RSI50.64Neutral
  3. CCIN/AN/A
  4. ROC 2520.29Bullish
  5. ROC 50N/AN/A
  6. Stoch KN/AN/A
  7. Stoch DN/AN/A
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper273.06Neutral
  3. BB Middle199.22Neutral
  4. BB Lower125.38Neutral
  5. ATR31.44High Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI44.46Neutral